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RESUMO: Introdução: O transplante de fígado (TF) continua sendo 
o melhor tratamento para pacientes, bem selecionados, portadores de 
carcinoma hepatocelular. Os critérios de Milão (CM) ( tumor único até 
5 cm e 3 tumores não maiores que 3 cms) são os critérios mais 
usados para estes pacientes. Nosso objetivo é avaliar a situação 
atual dos CM principalmente a sobrevida do paciente e a taxa 
livre de recorrência tumoral após 1 a 5 anos do TF, nos últimos 
10 anos. Material e Métodos: Revisamos 59 trabalhos entre 
200-2009; da Asia (42,3%), Europa (33,9%) e da América do 
Norte (20,4%). 5.525 pacientes submeteram-se ao TF com os 
CM. A sobrevida total dos pacientes e a taxa livre de recorrência 
tumoral foram analisados. Resultados: A taxa de sobrevida 
total dos pacientes foi em 1 ano de (87,26%), 2 anos (81,95%), 
3 anos (77,47%), 4 anos (75,24%) e 5 anos (72,41%). A taxa 
livre de recorrência tumoral foi de 80,29% e 71,36% em 1 e 5 
anos, respectivamente. Conclusão: A melhor taxa de sobrevida 
dos pacientes foi na América do Norte (88%) e na Asia (76,6%), 
respectivamente. Por outro lado, a Europa teve a melhor taxa 
livre de recorrência de doença em 5 anos (91,8%).
DEScRitORES: Transplante de fígado/normas; Carcinoma 
hepatocelular/terapia; Seguimentos.
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ABStRAct: Background: Orthotopic liver transplantation (OLT) 
remains an excellent treatment approach for HCC in well-selected 
candidates. Milan Criteria (MC) (a single tumor up to 5cm or up to 3 
tumors none larger than 3.0 cm) is the most widely used criteria for 
selection of those patients. Our aim is to study the current situation 
of the MC focusing on patient survival and tumor recurrence free 
rate from 1 to 5-yrs after OLT over the past 10 years. Material 
and Methods: We have reviewed 59 papers published between 
2000-2009; from Asia (42.3%), Europe (33.9%) and North America 
(20.4%). 5.525 patients have undergone OLT within MC. The overall 
patient survival rate and tumor recurrence free rate from 1 to 5-yrs 
were analyzed. Results: Overall patient survival rates were 1 year 
(87.26%), 2 years (81.95%), 3 years (77.47%), 4 years (75.24%) 
and 5 years (72.41%). We have found tumor recurrence free rate of 
80.29% and 71.36% at 1 and 5-yrs, respectively. Conclusion: MC 
has come to simplify the indication for LT in patients with HCC. The 
best patient survival rate at 1 and 5 years were in North America 
(88%) and Asia (76,6%), respectively. On the other hand, Europe 
had the best tumor recurrence free rate at 5 years (91.8%). 
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iNtRODUctiON
The most effective treatment options for hepatocellular carcinoma (HCC) are liver 
resection (LR) and orthotopic liver transplantion 
(OLT). However, LR is related with unsatisfactory high 
recurrence rate due to the fact tha it usually eliminates 
the tumor but not the underlying liver disease. On 
the other hand, OLT remains an excellent treatment 
approach for HCC in well-selected candidates1,2.
The most widely used criteria for patient 
selection are those proposed by Mazzaferro et al.3, the 
so-called Milan criteria (MC), (a single tumor up to 5cm 
or up to 3 tumors none larger than 3.0 cm). When MC 
were applied there was a significant improvement in 
survival over time mainly for HCC patients undergoing 
OLT. Currently, the 5-yr patient survival rate with MC 
is 61.1% contrasting with previously observed rate of 
25.3% in 1987.
Our aim is to study the current situation of the 
MC focusing on patient survival and tumor recurrence 
free rate from 1 to 5-yrs after OLT over the past 10 
years.
MAtERiAL AND MEtHODS
The data collected was based on the online 
database PUBMED. The key words applied on the 
search were MC, OLT and HCC limited to the period 
from 2000 to 2009.
We have found 477 articles in total, out of 59 
fulfilled our inclusion criteria: a) Papers that studied 
patients meeting Milan Criteria (single lesion smaller 
than 5 cm or up to 3 lesions smaller than 3 cm) and 
undergoing liver transplantation; b) Papers that 
reported both overall patient survival and tumor 
recurrence free rate in 1, 2, 3, 4 or 5 years.
Living donor or donor after cardiac death liver 
transplantation as well as radiological or pathological 
analysis, tumor size, gender and age were not 
considered in our search method.
RESULtS
Review of overall patient survival rate and tumor 
recurrence free rate on the 1st, 2nd, 3rd, 4th and 5th 
years in patients undergoing OLT for HCC within Milan 
Criteria are shown in Table 1.
table 1. Review of overall patient survival rate and tumor recurrence free rate on the 1st, 2nd, 3rd, 4th and 5th years in patients undergoing 
OLT for HCC within Milan criteria
 Patient Survival Rate (%) tumor Reccurrence Free Rate (%)
Ref Author Year N 1st 2nd 3rd 4th 5th 1st 2nd 3rd 4th 5th 
1 Jonas et al. 2001 Europe 120 90 NR NR NR 71 NR NR NR NR NR
2 Parolin et al. 2001 South America 8 NR NR NR NR NR 75 37,5 NR NR NR
3 Yao FY et al. 2002 North America 46 91 81 NR NR 72 NR NR NR NR NR
4 Khakhar A et al. 2003 North America 22 89,1 NR 80,2 NR 70,2 NR NR NR NR NR
5 Fernández JA et al. 2003 North America 33 82 NR NR NR 68 NR NR NR NR NR
6 Kaihara S et al. 2003 Asia 31 NR 87,4 NR NR NR NR NR NR NR NR
7 Kneteman NM et al. 2004 North America 19 94.1 NR NR 87.4 NR NR NR NR NR NR
8 Sun PL et al. 2004 Asia 12 NR NR NR NR NR 92 73 NR NR NR
9 Todo S et al. 2004 Asia 138 81.2 NR 78.7 NR NR NR NR NR NR NR
10 Santoyo J et al. 2005 Europe 30 80 NR 70 NR 70 NR NR NR NR NR
11 Merli M et al. 2005 Europe 49 90 85 NR NR NR NR NR NR NR NR
12 Herber S et al. 2005 Europe 17 NR NR NR NR NR 93,3 NR 82,5 NR 82,5
13 Tanaka H et al. 2005 Asia 279 NR NR NR NR NR 84 62 49 NR 29
14 Cheng YF et al. 2005 Asia 12 NR NR 79 NR NR NR NR NR NR NR
15 Malago M et al. 2006 Europe 17 NR 70 NR NR NR NR NR NR NR NR
16 Yokoi H et al. 2006 Asia 11 83 72 NR NR NR NR NR NR NR NR
17 Shah SA et al. 2006 North America 118* NR NR NR NR NR NR NR NR NR 78
17 Shah SA et al. 2006 North America 67** NR NR NR NR NR 95 88 88 85 85
18 Wai CT et al. 2006 Asia 22 91 NR 76 NR NR NR NR NR NR NR
19 Kishi Y et al. 2006 Asia 29 NR NR NR NR NR NR NR NR NR NR
20 Decaens T et al. 2006 Europe 279 87 82 78 72 70 NR NR NR NR NR
21 Yang SH et al. 2006 Asia 26 NR NR NR NR NR NR NR NR NR NR
22 Kim DY et al. 2006 Asia 57 86 NR 72 NR 67 NR NR NR NR NR
23 Oya H et al. 2006 Asia 8 NR NR NR NR NR 50 50 50 NR NR
Continua
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24 de Luque DP et al. 2006 Europe 81 80 NR 67 NR 61 60 30 10 10 10
25 Toso C et al. 2007 North America 34 85 NR NR 73 NR 85 NR NR 73 NR
26 Soejima Y et al. 2007 Asia 20 NR NR NR NR NR 100 100 100 NR NR
27 Shah AS et al. 2007 North America 155 87 NR 74 NR 65 NR NR NR NR NR
28 Parfitt JR et al. 2007 North America 50 NR NR 83 NR 83 NR NR NR NR NR
29 Cillo U et al. 2007 Europe 60 95 NR 85 NR NR NR NR NR NR NR
30 Poon RT et al. 2007 Asia 43 NR NR NR NR 81 NR NR NR NR 84
31 Onaca N et al. 2007 North America 631 NR NR NR NR NR 84,7 NR NR NR 61,8
32 Shah AS et al. 2007 North America 110 90 NR 70 NR 64 NR NR NR NR 79
33 Shen ZY et al. 2007 Asia 97 92 87,2 86,4 86,4 86,4 NR NR NR NR NR
34 Hwang S et al. 2007 Asia 3 NR 33 NR NR NR NR NR NR NR NR
35 Baccarani U et al. 2007 Europe 48 NR NR 79 NR 74 NR NR 74 NR 74
36 Bozorgzadeh A et al. 2007 North America 37 81,1 NR 57,04 NR 49,3 NR NR NR NR NR
37 Facciuto ME et al. 2008 North America 66 92 NR NR 62 NR NR NR NR NR NR
38 Castroagudín JF et al. 2008 Europe 98 85,1 NR 78,3 NR 70,1 NR NR NR NR NR
39 Silva M et al. 2008 Europe 231 85 NR 74 NR 72 NR NR NR NR NR
40 Andorno E et al. 2008 Europe 108 87,02 NR 74,53 NR 65,93 NR NR NR NR NR
41 Lee SG et al. 2008 Asia 164 86,6 NR 79,4 NR 76 NR NR NR NR NR
42 Zheng SS et al. 2008 Asia 72 94,3 NR 78,3 NR 78,3 87,3 NR 74 NR 69,7
43 Ravaioli M et al 2008 Europe 88 86 NR 77 NR 72 NR NR NR NR NR
44 Li J et al. 2009 Asia 24 NR 88,5 NR NR 88,5 NR NR NR NR NR
45 Chen JW et al. 2009 Oceania 112 88,4 NR 79,5 NR 74,3 NR NR NR NR NR
46 Vakili K et al. 2009 Asia 21 NR NR NR NR 87,1 NR NR NR NR NR
47 Kuo WT et al. 2009 Asia 14 92,9 NR 92,9 NR NR NR NR NR NR NR
48 Jang JW et al. 2009 Europe 37 89,2 70,3 NR NR 54,6 NR NR NR NR NR
49 Scatton O et al. 2009 Asia 279 NR NR NR NR 70 NR NR NR NR NR
50 Takada Y et al. 2009 Asia 74 NR NR NR NR 75 NR NR NR NR NR
51 Fujiki M el al. 2009 Asia 79 NR NR NR NR 77 NR NR NR NR NR
52 Xiao L et al. 2009 Asia 68 NR NR 88,4 NR NR NR NR 85,3 NR NR
53 Muscari F et al. 2009 Europe 73 NR NR NR NR 79 NR NR NR NR NR
54 Di Sandro S et al. 2009 Europe 126 NR NR 81,93 NR 75,43 NR NR 91,29 NR 90,37
55 Fan J et al. 2009 Asia 394 86,6 NR NR NR 78,8 65,2 NR NR NR 55,7
56
Sánchez Antolín G 
et al. 2009 Europe 42 NR NR NR 88,1 NR NR NR NR NR NR
57 Santoyo J et al. 2009 Europe 144 NR NR NR NR 65 NR NR NR NR NR
58 Qasim A et al. 2009 Europe 15 96 NR NR NR 84 NR NR NR NR NR
59 Mazzaferro V et al. 2009 Europe 444 NR NR NR NR 73,3 NR NR NR NR 94,5
OLT: orthotopic liver transplantation; HCC: hepatocellular carcinoma; Ref: Reference; NR: Not Reported, *Radiological Criteria; **Patological Criteria
 Patient Survival Rate (%) tumor Reccurrence Free Rate (%)
Ref Author Year N 1st 2nd 3rd 4th 5th 1st 2nd 3rd 4th 5th 
table 1. Review of overall patient survival rate and tumor recurrence free rate on the 1st, 2nd, 3rd, 4th and 5th years in patients undergoing 
OLT for HCC within Milan criteria                Continuação
From 2000 to 2009, 5525 patients have 
undergone liver transplantation within MC. Europe 
(38.1%) and Asia (35.8%) contributed with more 
than 70% of these patients while the others 30% 
have came from North America (23.9%) and Oceania 
(2%), Figure 1.
One year global overall patient survival rates 
was 87.2%, 2nd year- 81.9%, 3rd year- 77.4%, 4th year- 
75.2% and 5th year -72.4%, Figure 2.
One year patient survival rates were similar in 
North America, Europe, Asia and Oceania, while five 
year overall patient survival rate was slightly better in 
Asia (76.6%), Figure 3.
Europe had the best one and five years overall 
patient survival rates 86.7% and 70.9% respectively, 
Figure 3. North America had the best one year tumor 
recurrence free rate (85.6%) whereas Europe had the best 
five years tumor recurrence free rate (91.8%), Figure 4.
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Figure 1. Number of patients by continent: Europe (2107), North 



























Figure 2. Global patient survival rate: 1 year (87.26%), 2 year 
(81.94%), 3 year (77.4%), 4 year (75,23%) e 5 year (72,41%)
 

































































Figure 4. Tumor recurrence free survival rates from 1 to 5 year 
(by continent)
DiScUSSiON
HCC is a major health problem worldwide4. In 
the West 30-40% of HCC cases are detected at early 
stages and treated with intention to cure, a figure that 
reaches 60% of the cases in Japan4. Surgical treat-
ments are accepted as the standard of care for early 
tumors because they provide survival rates consis-
tently better than their untreated counterparts (5-yrs 
survival rates of 40-70% vs. < 20%)4,5,6,7.
Resection of single tumors in patients with well-
preserved liver function lead to remarkable outcomes 
(5-yrs survival exceeds 50-60%)(28. Early results after 
OLT in unselected patients with cirrhosis and HCC 
were poor, with early recurrence rates and 5-year 
survival of only 18-49%8-16. Several small studies in 
the early 1990s suggested that tumor recurrence-free 
survival could be improved by restricting transplan-
tation to patients with 2-3 nodules or a single tumor 
< 3-5 cm in diameter17-19. Two large retrospective 
studies confirmed that tumors > 5 cm had a high rate 
of post-transplantation recurrence, largely because 
of the association with vascular invasion and poor 
differention15,20.
The MC is considered the gold standard for 
selection of the best HCC candidates for OLT after 
numerous external validations of the seminal pro-
posed3. In fact the MC as a restriction selection for 
patients with HCC have been confirmed as consistent 
by several other groups among more than 1,000 
patients21-23. The MC were subsequently used by the 
United Network for Organ Sharing to assign the listing 
priority of patients presenting HCC.
cONcLUSiON
MC has come to simplify the indication for 
LT in patients with HCC. The best patient survival 
rate at 1 and 5 years were in North America (88%) 
and Asia (76.6%), respectively. On the other hand, 
Europe had the best tumor recurrence free rate at 5 
years (91.8%).
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